Current Stock Quote WGS GeneDx Holdings Corp Performance

Let's take a look at the current stock quote for WGS GeneDx Holdings Corp. As of the latest report, the stock price is steadily increasing, reflecting the company's growing presence in the genetic testing industry.

The company's revenue has been on the rise, with a significant increase in the number of genetic tests performed. This growth is a testament to the company's commitment to providing high-quality genetic testing services.

GeneDx Holdings Corp has established itself as a leader in the genetic testing market, with a strong reputation for accuracy and reliability. Its innovative approach to genetic testing has helped the company stay ahead of the competition.

The company's stock price has shown a steady upward trend, making it an attractive investment opportunity for those interested in the genetic testing industry.

Broaden your view: Fs Kkr Capital Corp Stock Price

The stock performance of GeneDx Holdings is quite impressive. The current share price is $79.24, with a 52-week high of $98.87 and a low of $3.62.

GeneDx Holdings has experienced significant growth over the past year, with a 1-year change of 2,001.86%. This is a remarkable increase, but it's essential to consider the 3-year change, which is -27.01%.

The stock's beta is 2.09, indicating a relatively high level of volatility. This means that the stock's price may fluctuate more significantly than the overall market.

Here's a summary of the company's performance over the past year:

WGS stock is a genomics company that provides personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery.

The company's valuation is a concern, with a Snowflake Score of 0/6, indicating a potentially overvalued stock. On the other hand, WGS has a strong future growth potential, with a Snowflake Score of 4/6.

WGS's past performance is a mixed bag, with a Snowflake Score of 0/6, indicating no significant growth or stability. However, the company's financial health is relatively solid, with a Snowflake Score of 5/6.

Here's a summary of WGS's key statistics:

The company's stock price has been quite volatile, with a 1-year change of 2,001.86% and a 3-year change of -27.01%. This suggests that WGS's stock price can be quite unpredictable, making it a high-risk investment.

Discover more: S B I Card Share Price

As an investor, it's essential to understand the performance of WGS compared to the broader market and its industry peers. WGS has exceeded the US Healthcare industry, which returned 2% over the past year.

The 1-year return of WGS is a staggering 2,001.9%, significantly outperforming the US Market's 22.7% return.

Here's a quick comparison of WGS's performance over different time frames:

If you're considering investing in WGS, keep in mind that its performance has been exceptional compared to the broader market and its industry peers.

GeneDx reported a narrower Q3 loss, which is a positive sign for investors. The company's revenues surged, indicating a strong financial performance.

This is a significant improvement from previous quarters, showing that GeneDx is on the right track. GeneDx is a leader in delivering improved health outcomes through genomic insights.

The company's annual guidance was also lifted, suggesting that GeneDx is confident in its future financial prospects. This is a vote of confidence from the company itself, and it may give investors a reason to be optimistic about the stock's potential.

GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. GeneDx Holdings WGS stock is trading higher on Tuesday.

GeneDx, a leader in delivering improved health outcomes through genomic insights, reported a narrower Q3 loss. The company's revenues surged, leading to an update of its annual guidance.

GeneDx's exome sequencing products can be used to search for and diagnose hundreds of genes. This technology has contributed to the company's revenue growth.

GeneDx announced its Q3 results in a press release, citing the Journal of the American Medical Association as a publication that has featured its work. GeneDx is now trading higher on the news.

Suggestion: Ianthus Capital Holdings Inc Stock Price

The company's financial data shows a significant focus on returning value to shareholders through dividend payments and share buybacks.

Their 3-year average share buyback ratio is a notable -52.8, indicating a substantial amount of shares have been repurchased over this period.

This is also reflected in their shareholder yield, which is -2.06%.